.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Lucio N. Gordan, MD

Articles

When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

January 16th 2025

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.

The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types

January 16th 2025

Panelists discuss how comprehensive biomarker testing enables detection of actionable mutations across cancer types, informing targeted therapy selection. This broad molecular profiling approach can reveal treatment opportunities regardless of tumor origin.

Key Considerations When Ordering Biomarker Testing

December 24th 2024

Panelists discuss how optimal biomarker testing requires careful balancing of multiple factors. Critical considerations include the turnaround time needed to inform timely treatment decisions, the comprehensiveness of testing panels to identify actionable mutations, and the demonstrated clinical utility of results for guiding therapy selection. Patient-specific factors such as cancer type, stage, prior treatments, and urgency of therapeutic decisions must guide test selection.